Agent | Antibiotic | Level of evidence | Strength of recommendation |
---|---|---|---|
MRSA | Tigecycline# | 2 | A |
Linezolid+ | 3 | A | |
Daptomycin+ | 4 | C | |
Vancomycin+ | 4 | B | |
Cotrimoxazole+ | 4 | C | |
VRE | Tigecycline# | 2 | A |
Linezolid+ | 3 | A | |
ESBL-producing (E. coli, Klebsiella spp.) | Imipenem | 3 | A |
Meropenem | 3 | A | |
Doripenem | 3 | A | |
Ertapenem# | 3 | A | |
Tigecycline# | 2 | A | |
Acylaminopenicillin/BLI | 3 | A | |
Fosfomycinâ—Š | 4 | B | |
Pseudomonas spp. | Imipenem | 4 | A |
Meropenem | 4 | A | |
Doripenem | 4 | A | |
Acylaminopenicillin/BLI | 4 | A | |
Cefepim | 4 | A | |
Aminoglycosideâ—Š | 4 | B | |
Ciprofloxacin* | 4 | A | |
Levofloxacin* | 4 | A | |
Acinetobacter spp. | Colistin | 2 | A |
Tigecycline# | 4 | A | |
Carbapenemase-producing (i.e. KPC)species | Tigecycline# | 4 | A |
Colistin | 4 | B |